Eyenovia

17 articles with Eyenovia

• Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia

  6/4/2019

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it has initiated its MicroPine Phase III program with the first patient enrolled in its CHAPERONE study.

• Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia

  2/6/2019

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate the CHAPERONE study - the Company's Phase III registration trial of MicroPine to reduce the progression of myopia in children.

• Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis

  1/30/2019

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced positive results from the MicroStat Phase 3 MIST-1 study.

• 

  A Look at the Year's Most and Least Successful Biotech IPOs

  1/3/2019

  Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.

• Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study

  12/3/2018

  Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019

• Eyenovia Announces Publication of its PG21 Phase II Trial Results Demonstrating Robust IOP Lowering Effect and Patient Usability

  11/28/2018

  Eyenovia, Inc. (NASDAQ: EYEN) today announced that the full results of its Phase II PG21 study have been published in the article “Latanoprost with high precision, piezo-print microdose delivery for IOP lowering: clinical results of the PG21 study of 0.4 µg daily microdose” in the November issue of the peer-review journal Clinical Ophthalmology

• Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1

  11/26/2018

  Topline results for Phase III MicroStat program expected H1 2019

• Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study

  11/26/2018

  Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has enrolled the first patient in the first of two Phase III trials (MIST-1 and MIST-2) of the Company’s MicroStat program for pharmacologic mydriasis, or dilation of the pupil for an eye exam.

• 

  Biotech IPOs Are Booming … but for How Long?

  9/19/2018

  According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.

• SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Eyenovia, Inc. (EYEN)

  8/16/2018

  Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Eyenovia, Inc.

• Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability

  8/13/2018

  Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced positive results of its EYN PG21 proof-of-concept study of microdose latanoprost for the lowering of intraocular pressure (IOP) and patient usability.

• Eyenovia Announces Closing of $27.3M Initial Public Offering

  1/30/2018

  Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services and Roth Capital Partners acted as joint book-running managers for the offering.

• 

  New York's Eyenovia Preps for $30M IPO

  1/11/2018

  The company plans to offer 2.73 million shares priced between $10 and $12 each.

• Eyenovia Announces Appointment of John Gandolfo as Chief Financial Officer

  1/9/2018

  Eyenovia announced the appointment of John Gandolfo as Chief Financial Officer (CFO) effective December 18, 2017.

• Eyenovia Publication of EYE 102 Phase II Results Demonstrates Strong Pharmacodynamic Effect, Tolerability and Reduced Systemic Exposure of High-Precision Micro-dosing compared to Conventional Eyedroppers

  10/31/2017

  Eyenovia's micro-dose delivery of topical phenylephrine achieves comparable dilation results with a dose one-quarter the volume of a conventional pipette eye dropper.

• Eyenovia Announces Completion Of Second Phase II Study

  12/20/2016

• Eyenovia Announces Publication Of Phase II Study Results Demonstrating Benefits Of Micro-Formulation Over Conventional Eyedroppers And Addition Of Scientific Advisory Board Members

  11/29/2016